Table 1 Targeted immunopanels and pitfalls when determining cancer site of origin.
From: Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls
Primary tumor | Pertinent positive immunohistochemistry | Pertinent negative immunohistochemistry | Potential pitfalls |
|---|---|---|---|
ER+ breast cancer | ER, GCDFP, MMGB, GATA3, CK7 | CK20, TTF-1, CDX2 | |
ER− breast cancer | GATA3, Sox10, cytokeratin | ER, GCDFP, MMGB | Melanoma is S-100+/Sox10+ |
Melanoma | S-100, Sox10, HMB45, Melan A, MITF | Cytokeratin | TNBC can be S-100+/Sox10+ |
Lung adenocarcinoma | TTF-1, Napsin A | Can be GATA3+/ER+ | |
High-grade serous | ER, WT-1, PAX8 | GATA3, GCDFP | Breast cancer can be WT-1+ |
Prostate cancer | PSA, P501S, NKX3.1 | ER, GATA3 | ILC and male IDC can be NXK3.1+ |
GI adenocarcinoma | CDX2, CK20, or CK7 | DPC4 (subset) | Can be GATA3+ |
